AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Submission of Matters to a Vote of Security Holders

ME Staff 8-k
-
0

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders.

On June18, 2018, AVEO Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted on the following proposals:

1. The following nominees were elected to the Company’s Board of Directors for terms expiring at the 2019 annual meeting of stockholders.

For Withheld BrokerNon- Votes

Mr.MichaelP. Bailey

 49,464,917 305,265 49,543,430

Mr.KennethM. Bate

 47,837,807 1,932,375 49,543,430

Dr.AnthonyB. Evnin

 49,459,199 310,983 49,543,430

Mr.JohnH. Johnson

 48,179,436 1,590,746 49,543,430

Dr.RobertC. Young

 49,366,496 403,686 49,543,430

2. A non-binding, advisory proposal on the compensation of the Company’s named executive officers was approved.

For:

 48,704,579

Against:

 783,037

Abstain:

 282,566

Broker Non-Votes:

 49,543,430

3. The appointment of Ernst& Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December31, 2018 was ratified.

For:

 98,604,832

Against:

 498,600

Abstain:

 210,180

Broker Non-Votes:


About AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).